gemcitabine has been researched along with T-Cell Lymphoma in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, R; Liang, Y; Liu, X; Piao, Y; Wang, L; Wei, L | 1 |
| Hara, S; Hiramoto, N; Ishikawa, T; Nishikubo, M; Sawamura, N; Shimomura, Y; Yamaguchi, T | 1 |
| Agostoni, V; Couvreur, P; Gref, R; Lampropoulou, M; Lazarou, YG; Maksimenko, A; Rodriguez-Ruiz, V; Salzano, G; Yannakopoulou, K | 1 |
| Mangone, M; Marchi, E; O'Connor, OA; Zullo, K | 1 |
| Bellei, M; Biasoli, I; Bonacorsi, G; Cesaretti, M; Federico, M; Luminari, S; Maiorana, A; Quaresima, M; Salati, M | 1 |
| Qian, Z; Song, Z; Wang, H; Wang, X; Zhang, H; Zhao, J | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| Duvic, M | 1 |
| Dong, M; Gui, L; He, XH; Li, YX; Liu, P; Shi, YK; Wang, JJ; Wang, WH; Yang, JL; Yang, S; Zhang, CG; Zhou, SY | 1 |
| Higuchi, Y; Kato, H; Kinoshita, T; Nakamura, S; Saito, T; Taji, H; Yamamoto, H; Yamamoto, K; Yatabe, Y | 1 |
| Cavalli, F; Mazzucchelli, L; Mora, O; Soldini, D; Zucca, E | 1 |
| Vose, JM | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Fina, M; Gandolfi, L; Pellegrini, C; Pileri, S; Quirini, F; Stefoni, V; Venturini, F; Zinzani, PL | 1 |
| Sun, WZ; Zhang, QY; Zhao, S | 1 |
| Chen, HT; Peng, PJ; Zhang, HY | 1 |
| Farid, M; Koo, GC; Lim, ST; Loong, S; Quek, R; Tao, M; Tay, K; Yau, YW | 1 |
| Ashley, S; Yim, KL | 1 |
| Archer, CD; Catovsky, D; Chau, I; Cunningham, D; Gill, K; Harries, M; Hill, M; Koh, DM; Norman, AR; Prior, Y; Ross, PJ; Uzzell, M; Wotherspoon, A | 1 |
| Colovos, C; Emmanouilides, C; Hernandez, L; Pinter-Brown, L; Rosen, P; Schiller, G; Territo, M | 1 |
| Crump, M; Lin, B; Shepherd, L | 1 |
| Nguyen, NP; Sallah, S; Wan, JY | 1 |
| Bouafia, F; Bourgeois, E; Coiffier, B; Dumontet, C; Hequet, O; Leleu, X; Morschhauser, F; Salles, G; Solal-Celigny, P; Thieblemont, C | 1 |
1 review(s) available for gemcitabine and T-Cell Lymphoma
| Article | Year |
|---|---|
Update on T-cell lymphoma.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Geography; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Survival Analysis; World Health Organization | 2008 |
8 trial(s) available for gemcitabine and T-Cell Lymphoma
| Article | Year |
|---|---|
Pralatrexate pharmacology and clinical development.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Depsipeptides; Disease-Free Survival; Drug Approval; Drug Synergism; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Vorinostat | 2015 |
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Recurrence; Skin Neoplasms; Time Factors; Treatment Outcome | 2010 |
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hodgkin Disease; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Male; Methylprednisolone; Middle Aged; Recurrence; Survival Rate | 2003 |
Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hodgkin Disease; Humans; Infusions, Intravenous; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Pilot Projects; Racial Groups; Recurrence | 2004 |
A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytarabine; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Rituximab | 2005 |
Treatment of refractory T-cell malignancies using gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukemia, Prolymphocytic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Recurrence; Salvage Therapy; Treatment Outcome | 2001 |
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites; Capillary Leak Syndrome; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Myocardial Infarction; Pulmonary Veno-Occlusive Disease; Recurrence; Renal Insufficiency; Survival Rate; Thrombocytopenia; Time Factors | 2001 |
13 other study(ies) available for gemcitabine and T-Cell Lymphoma
| Article | Year |
|---|---|
Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Etoposide; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Neoplasm Staging; Treatment Outcome | 2023 |
Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Kidney; Lymphoma, T-Cell; Middle Aged; Thrombotic Microangiopathies | 2021 |
Positively charged cyclodextrins as effective molecular transporters of active phosphorylated forms of gemcitabine into cancer cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Breast Neoplasms; Cyclodextrins; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Models, Theoretical; Phosphorylation; Tumor Cells, Cultured | 2017 |
Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Italy; Lymphoma, T-Cell; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Recurrence; Registries; Regression Analysis; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome; Young Adult | 2015 |
Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Middle Aged; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2015 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat | 2015 |
GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Middle Aged; Natural Killer T-Cells; Neoplasm Recurrence, Local; Neoplasm Staging; Nose Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphadenopathy; Lymphatic Metastasis; Lymphoma, T-Cell; Receptors, CCR4; Salvage Therapy; Tomography, X-Ray Computed | 2017 |
Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Celiac Disease; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Recurrence | 2008 |
[Gemcitabine combined with cisplatin and methylprednisolone sodium succinate in chemotherapy for relapsed or refractory T cell non-Hodgkin lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Methylprednisolone Hemisuccinate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 2010 |
[Rituximab-mediated sensitization of B-NHL cell lines to apoptosis induced by gemcitabine and Navelbine in vitro].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lymphoma, T-Cell; Proto-Oncogene Proteins c-bcl-2; Rituximab; Vinblastine; Vinorelbine | 2010 |
A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Outcome | 2011 |
Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell; Male; Methylprednisolone; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |